ReviewHuman vaccines & immunotherapeutics2026
Tertiary lymphoid structures guided opportunities and challenges for immunotherapy in early gastroesophageal junction cancer and low rectal cancer.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-stage gastroesophageal junction cancer (GEJC) and low rectal cancer (LRC) pose a dilemma: surgery is often curative yet may cause lasting functional loss. Emerging data suggest that early tumors tend to exhibit an immune-active microenvironment with greater tertiary lymphoid structures (TLS) density and maturity, whereas advanced disease is frequently marked by immunosuppressive signaling, vascular and metabolic barriers, and attenuated TLS function. This review synthesizes stage-dependent immune ecology and evaluates how TLS biology may inform immunotherapy in early GEJC and LRC. We highlight opportunities for organ preservation in selected patients and key constraints: few trials in early-stage tumor, uncertain applicability beyond MSI-H or dMMR, limited performance of current biomarkers, challenges in assessing pathologic complete response, and the need for standardized surveillance when surgery is deferred. Overall, TLS-guided selection and rational microenvironment-modulating combinations appear promising, but replacing surgery should be confined to trials with rigorous endpoints and quality-of-life evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.